The biotechnology industry's resurgence that started late last year has been pushed to a large extent by genomics companies, whose scientific progress and stock gains helped draw the attention of mainstream media and investors.

This explosive niche of biotechnology is highlighted in a new report from BioWorld called, "2000 Genomics Review: New Technologies for the New Millennium." It includes extensive profiles of 22 public companies and 51 private companies, including the significant international players. It also includes details on about 650 genomics collaborations. The report features stories on the industry, bioinformatics and ethical issues, as well as on key discoveries. The information is up to date, and includes news disclosed well into January.

Stock gains of more than 300 percent in 1999 were seen by leaders in the industry, including Human Genome Sciences Inc., Millennium Pharmaceuticals Inc. and Aurora Biosciences Inc. Even greater percentage gains were registered by Affymetrix Inc., CuraGen Corp., Genome Therapeutics Corp. and Celera Genomics.

Interest in genomics companies will only increase as the Human Genome Project nears completion and drugs begin emerging from this research.

The explosion in this sector is evidenced by the size of the report: 272 pages, more than twice as large as BioWorld's 1999 Genomics Review.

To purchase the new report or for further information, call 1-800-688-2421 or (404) 262-5476.